For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Biogen Idec Ma Inc.

USPTO Granted Patents = 216

CIPO Patents = 11

EPO Patents = 67

Trademarks = 16

Forward Citations = 1,950

Loading Chart...

Loading Chart...

275 inventors (with patents filed for the assignee):

Jeffrey L Browning (29 out of 43 patents)

R Blake Pepinsky (27 out of 51 patents)

Ellen A Garber (27 out of 35 patents)

4. Alexey Alexandrovich Lugovskoy (15 out of 50 patents)

5. Christine Ambrose (14 out of 17 patents)

6. Sha Mi (14 out of 34 patents)

7. Yen-Ming Hsu (13 out of 26 patents)

8. Jeffrey Thompson (13 out of 16 patents)

9. Anthony Rossomando (12 out of 15 patents)

10. Linda C Burkly (12 out of 23 patents)

11. Jose William Saldanha (11 out of 48 patents)

12. Paul David Rennert (10 out of 33 patents)

13. Scott Glaser (10 out of 19 patents)

14. Gnanasambandam Kumaravel (9 out of 60 patents)

15. Antonin De Fougerolles (9 out of 91 patents)

Core Competencies:

Cognitive Composite Parameters

Nogo Receptor Antagonists

Anti-BCMA Antibodies

Bruton's Tyrosine Kinase Inhibitors

Transforming Growth Factor Beta Proteins

Immune Response Evaluation

Mammalian Cell Production

Neuronal Survival Promotion

Inflammatory Bowel Disease Treatment

Polypeptide Compositions

Antibody Derivatives

Bioproduct Production Control

216 patents: Sort by Forward Citations

1. 9717453 - Cognitive composite parameters and uses thereof for evaluating multiple sclerosis (2017-08-01),

2. 9228015 - Nogo receptor antagonists and methods of increasing neurite outgrowth (2016-01-05),

3. 9212379 - Nutrient monitoring and feedback control for increased bioproduct production (2015-12-15),

4. 9034324 - Anti-BCMA antibodies (2015-05-19),

5. 9029359 - Heteroaryl Btk inhibitors (2015-05-12),

6. 9011859 - Methods for treating TWEAK-related conditions (2015-04-21),

7. 9005926 - Methods of preventing and removing trisulfide bonds (2015-04-14),

8. 8992924 - [object Object] (2015-03-31),

9. 8980610 - Arginine inactivation of viruses (2015-03-17),

10. 8969042 - Refolding transforming growth factor beta family proteins (2015-03-03),

11. 8961976 - Anti-CD154 antibodies (2015-02-24),

12. 8932821 - NOGO receptor binding protein (2015-01-13),

13. 8932574 - Stable liquid interferon beta formulations (2015-01-13),

14. 8900577 - Immunoglobulin formulation and method of preparation thereof (2014-12-02),

15. 8894999 - Use of DR6 and p75 antagonists to promote survival of cells of the nervous system (2014-11-25),

Biogen is a multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. As a pioneer in neuroscience research, Biogen focuses on developing innovative treatments for conditions such as multiple sclerosis (MS), Alzheimer's disease, and spinal muscular atrophy (SMA). With a commitment to transforming patients' lives, Biogen continues to advance scientific knowledge and redefine possibilities in the field of neuroscience.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

216 Patents

#15 in Cambridge, MA

#112 in Massachusetts

#1,863 in US

#3,847 in the World

Cambridge, MA, United States of America

Biogen Idec Ma Inc.

Forward Citations = 1,950

275 inventors:

Jeffrey L Browning (29 out of 43 patents)

R Blake Pepinsky (27 out of 51 patents)

Ellen A Garber (27 out of 35 patents)

4. Alexey Alexandrovich Lugovskoy (15 out of 50 patents)

5. Christine Ambrose (14 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…